Precautionary Batch Withdrawals: Recall Readiness for Marketing Authorisation Holders

When PRAC reviewed immunoglobulin hypersensitivity reports in October 2026, batches of several products had already been withdrawn as a precaution in certain Member States. The episode is a reminder that recall readiness is a core regulatory capability.

What a precautionary withdrawal involves

A precautionary withdrawal is taken before the cause of a problem is confirmed. It requires fast decisions about scope, communication to wholesalers and pharmacies, and notification to the competent authorities in each affected country.

Elements of a workable procedure

  • Clear decision authority. Who decides, who is deputised and how the decision is recorded.
  • Distribution traceability. The ability to identify every consignee of a batch quickly.
  • Authority notification. Contact lists for each market, including EOF in Greece, kept current.
  • Customer communication. Pre-approved templates for different classes of recall.
  • Reconciliation. Evidence of how much product was returned, quarantined or destroyed.

Interfaces that are often missed

Quality, regulatory affairs and pharmacovigilance each hold part of the picture. Complaint data, adverse event reports and deviation records should be reviewed together, and the QPPV and the Qualified Person should be able to talk to each other within hours, not days.

Testing the procedure

Mock recalls reveal gaps that documents do not. Measuring the time taken to trace a batch to its customers, and to contact them, gives an honest view of readiness and is looked at favourably in inspections.

How PQRA helps

PQRA reviews recall and field action procedures, runs mock recall exercises, and supports GDP and GMP inspection readiness so that a real event is managed in a controlled way.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *